

HSCT Mortality Endpoints by Quarter: 2025 Transplant Cohort

Quarterly Analysis of NRM, TRM, and Relapse-Related Mortality

Transplant Outcomes Analysis

2026-01-21

Note

This report was generated using AI under general human direction. At the time of generation, the contents have not been comprehensively reviewed by a human analyst.

Executive Summary

This report analyzes mortality endpoints for **26 patients** who underwent HSCT during calendar year 2025, broken down by quarter (trimester).

Mortality Endpoints Analyzed:

1. **Non-Relapse Mortality (NRM):** Deaths from transplant-related complications (not disease relapse)
2. **Transplant-Related Mortality (TRM):** Equivalent to NRM in this analysis
3. **Relapse-Related Mortality:** Deaths from disease relapse/progression

Quarterly Distribution:

- ****Q1 2025**:** 7 transplants
- ****Q2 2025**:** 4 transplants
- ****Q3 2025**:** 8 transplants
- ****Q4 2025**:** 7 transplants

Overall Mortality Results:

- **Total Deaths:** 1 (3.8%)

- **NRM/TRM Events:** 1 (3.8%)
- **Relapse Deaths:** 0 (0%)

Limited Follow-up Period

This cohort has **limited follow-up time** with transplants occurring throughout 2025. Earlier quarters have longer follow-up, while Q4 2025 patients have minimal follow-up time. Results should be interpreted with caution, especially for late timepoints (365 days).

Methodology

Endpoint Definitions

****Non-Relapse Mortality (NRM):****

- Deaths from any cause OTHER THAN disease relapse
- Includes: GVHD, infections, organ toxicity, other transplant complications
- In this analysis: NRM = TRM

****Transplant-Related Mortality (TRM):****

- Deaths from transplant-related complications
- Equivalent to NRM in this dataset
- Includes: GVHD, infections, organ toxicity, other transplant complications

****Relapse-Related Mortality:****

- Deaths from disease relapse or progression
- Excludes all transplant-related complications

****Current Cohort Events:****

- NRM/TRM: 1 event(s)
- Relapse Deaths: 0 event(s)

Calculation Methods

All mortality rates calculated as **simple percentages**:

- **Mortality Rate (%) = (Number of Events / Total N) × 100**
- Results shown as: “events/total (percentage%)”
- Calculated at Day 30, Day 100, and Day 365 post-transplant

Non-Relapse Mortality (NRM) Analysis

NRM by Quarter - Overall

Table 1: Non-Relapse Mortality at 30, 100, and 365 Days by Quarter

Quarter	N	Day 30		Day 100		Day 365	
		Events	NRM Rate (n/N %)	Events	NRM Rate (n/N %)	Events	NRM Rate (n/N %)
Q1 2025	7	0	0/7 (0%)	0	0/7 (0%)	0	0/7 (0%)
Q2 2025	4	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)
Q3 2025	8	0	0/8 (0%)	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	7	1	1/7 (14.3%)	1	1/7 (14.3%)	1	1/7 (14.3%)

NRM by Quarter and Complete Remission Status

Table 2: Non-Relapse Mortality by Quarter and Complete Remission Status

Quarter	Disease Status	N	Day 30		Day 100	
			Events	NRM Rate (n/N %)	Events	NRM Rate (n/N %)
Q1 2025	Complete Remission	5	0	0/5 (0%)	0	0/5 (0%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q3 2025	Complete Remission	8	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	Complete Remission	5	1	1/5 (20%)	1	1/5 (20%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)

NRM by Quarter and Donor Type

Table 3: Non-Relapse Mortality by Quarter and Donor Type

Quarter	Donor Type	N	Day 30		Day 100		Events
			Events	NRM Rate (n/N %)	Events	NRM Rate (n/N %)	
Q1 2025	MUD	4	0	0/4 (0%)	0	0/4 (0%)	0
Q1 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q1 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0
Q2 2025	MUD	1	0	0/1 (0%)	0	0/1 (0%)	0
Q2 2025	Sibling HLA-identical	2	0	0/2 (0%)	0	0/2 (0%)	0
Q2 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0
Q3 2025	Haploidentical	3	0	0/3 (0%)	0	0/3 (0%)	0
Q3 2025	MMUD	3	0	0/3 (0%)	0	0/3 (0%)	0
Q3 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q4 2025	Haploidentical	3	1	1/3 (33.3%)	1	1/3 (33.3%)	1
Q4 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q4 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)	0

NRM by Quarter, Donor Type, and CR Status

Table 4: Non-Relapse Mortality by Quarter, Donor Type, and Complete

Quarter	CR Status	Donor Type	N	Day 30		Events
				Events	NRM Rate (n/N %)	
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)	0
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)	0
Q1 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)	0
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)	0
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)	0
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	0/2 (0%)	0
Q3 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)	0
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)	0
Q3 2025	Complete Remission	MUD	2	0	0/2 (0%)	0
Q4 2025	Complete Remission	Haploidentical	3	1	1/3 (33.3%)	1
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)	0

Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)	0
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)	0
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)	0

Transplant-Related Mortality (TRM) Analysis

i TRM = NRM in This Analysis

In this dataset, Transplant-Related Mortality (TRM) is equivalent to Non-Relapse Mortality (NRM). Both terms refer to deaths from transplant complications rather than disease relapse. The tables below show the same data as the NRM section above, labeled as TRM for completeness.

TRM by Quarter - Overall

Table 5: Transplant-Related Mortality at 30, 100, and 365 Days by Quarter

Quarter	N	Day 30		Day 100		Day 365	
		Events	TRM Rate (n/N %)	Events	TRM Rate (n/N %)	Events	TRM Rate (n/N %)
Q1 2025	7	0	0/7 (0%)	0	0/7 (0%)	0	0/7 (0%)
Q2 2025	4	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)
Q3 2025	8	0	0/8 (0%)	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	7	1	1/7 (14.3%)	1	1/7 (14.3%)	1	1/7 (14.3%)

TRM by Quarter and Complete Remission Status

Table 6: Transplant-Related Mortality by Quarter and Complete Remission Status

Quarter	Disease Status	N	Day 30		Day 100	
			Events	TRM Rate (n/N %)	Events	TRM Rate (n/N %)
Q1 2025	Complete Remission	5	0	0/5 (0%)	0	0/5 (0%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)

Q2 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q3 2025	Complete Remission	8	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	Complete Remission	5	1	1/5 (20%)	1	1/5 (20%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)

TRM by Quarter and Donor Type

Table 7: Transplant-Related Mortality by Quarter and Donor Type

Quarter	Donor Type	N	Day 30		Day 100		Events
			Events	TRM Rate (n/N %)	Events	TRM Rate (n/N %)	
Q1 2025	MUD	4	0	0/4 (0%)	0	0/4 (0%)	0
Q1 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q1 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0
Q2 2025	MUD	1	0	0/1 (0%)	0	0/1 (0%)	0
Q2 2025	Sibling HLA-identical	2	0	0/2 (0%)	0	0/2 (0%)	0
Q2 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0
Q3 2025	Haploidentical	3	0	0/3 (0%)	0	0/3 (0%)	0
Q3 2025	MMUD	3	0	0/3 (0%)	0	0/3 (0%)	0
Q3 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q4 2025	Haploidentical	3	1	1/3 (33.3%)	1	1/3 (33.3%)	1
Q4 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)	0
Q4 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)	0

TRM by Quarter, Donor Type, and CR Status

Table 8: Transplant-Related Mortality by Quarter, Donor Type, and CR Status

Quarter	CR Status	Donor Type	N	Day 30		Events
				Events	TRM Rate (n/N %)	
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)	0
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)	0
Q1 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)	0
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)	0
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)	0

Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	0/2 (0%)	0
Q3 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)	0
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)	0
Q3 2025	Complete Remission	MUD	2	0	0/2 (0%)	0
Q4 2025	Complete Remission	Haploidentical	3	1	1/3 (33.3%)	1
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)	0
Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)	0
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)	0
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)	0

Relapse-Related Mortality Analysis

Relapse Mortality by Quarter - Overall

Table 9: Relapse-Related Mortality at 30, 100, and 365 Days by Quarter

Quarter	N	Day 30		Day 100		Day 365	
		Events	Relapse Mortality (n/N %)	Events	Relapse Mortality (n/N %)	Events	Relapse Mortality (n/N %)
Q1 2025	7	0	0/7 (0%)	0	0/7 (0%)	0	0/7 (0%)
Q2 2025	4	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)
Q3 2025	8	0	0/8 (0%)	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	7	0	0/7 (0%)	0	0/7 (0%)	0	0/7 (0%)

Relapse Mortality by Quarter and Complete Remission Status

Table 10: Relapse-Related Mortality by Quarter and Complete Remission Status

Quarter	Disease Status	N	Day 30		Day 100	
			Events	Relapse Mortality (n/N %)	Events	Relapse Mortality (n/N %)
Q1 2025	Complete Remission	5	0	0/5 (0%)	0	0/5 (0%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)

Q3 2025	Complete Remission	8	0	0/8 (0%)	0	0/8 (0%)
Q4 2025	Complete Remission	5	0	0/5 (0%)	0	0/5 (0%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)	0	0/2 (0%)

Relapse Mortality by Quarter and Donor Type

Table 11: Relapse-Related Mortality by Quarter and Donor Type

Quarter	Donor Type	N	Day 30		Day 100	
			Events	Relapse Mortality (n/N %)	Events	Relapse Mortality (n/N %)
Q1 2025	MUD	4	0	0/4 (0%)	0	0/4 (0%)
Q1 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)
Q1 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)
Q2 2025	MUD	1	0	0/1 (0%)	0	0/1 (0%)
Q2 2025	Sibling HLA-identical	2	0	0/2 (0%)	0	0/2 (0%)
Q2 2025	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)
Q3 2025	Haploidentical	3	0	0/3 (0%)	0	0/3 (0%)
Q3 2025	MMUD	3	0	0/3 (0%)	0	0/3 (0%)
Q3 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)
Q4 2025	Haploidentical	3	0	0/3 (0%)	0	0/3 (0%)
Q4 2025	MMUD	2	0	0/2 (0%)	0	0/2 (0%)
Q4 2025	MUD	2	0	0/2 (0%)	0	0/2 (0%)

Relapse Mortality by Quarter, Donor Type, and CR Status

Table 12: Relapse-Related Mortality by Quarter, Donor Type, and CR Status

Quarter	CR Status	Donor Type	N	Day 30		Events	Relapse Mortality (n/N %)	Events	Relapse Mortality (n/N %)
				Events	Relapse Mortality (n/N %)				
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)	0	0/3 (0%)	0	0/3 (0%)
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q1 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)	0	0/1 (0%)	0	0/1 (0%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	0/2 (0%)	0	0/2 (0%)	0	0/2 (0%)

Q3 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)
Q3 2025	Complete Remission	MUD	2	0	0/2 (0%)
Q4 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)

Summary and Key Findings

Mortality Event Summary

Table 13: Summary of Mortality Endpoints - 2025 Cohort

Mortality Endpoint	Total Events (N=26)	Overall Rate
Non-Relapse Mortality (NRM)	1	3.8%
Transplant-Related Mortality (TRM)	1	3.8%
Relapse-Related Mortality	0	0%
Total Deaths	1	3.8%

Key Observations

****Non-Relapse Mortality (NRM):****

- Total NRM events: 1 (3.8%)
- NRM occurred in Complete Remission patients
- No NRM in Not in CR group

****Transplant-Related Mortality (TRM):****

- Equivalent to NRM in this analysis

- Total TRM events: 1 (3.8%)\n

- Cause: Infection with GVHD\n\n

****Relapse-Related Mortality:****

- Total relapse deaths: 0 (0%)\n

- No relapse-related deaths observed in this cohort to date\n\n

****Overall:****

- Excellent early mortality outcomes\n

- Limited follow-up time affects long-term endpoint assessment\n

- Longer follow-up needed for 1-year mortality rates\n

! Important Limitations

Limited Follow-up: - Median follow-up: 169 days - Q4 2025 patients: Very short follow-up time - 365-day endpoints: Not yet reached for most patients

Interpretation: - Early mortality endpoints (Day 30, Day 100) are more reliable - One-year (Day 365) results should be interpreted with extreme caution - True NRM and relapse mortality rates may increase with longer follow-up

Report generated on January 21, 2026

Analysis includes only patients transplanted in calendar year 2025, organized by quarter (trimester)

Mortality endpoints: NRM, TRM, and Relapse-Related Mortality calculated separately